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Abstract
MK-801 induces psychotomimetic behavioural changes in animals. ERKs play an important role in the
pathogenesis of schizophrenia and in the action of antipsychotics and psychotomimetics. We observed
phosphorylation of ERK-signalling-pathway-associated molecules in the rat frontal cortex and their as-
sociation with rat behaviour after MK-801 administration. After injecting 0.25–1 mg/kg MK-801, ERK
phosphorylation decreased compared to vehicle treatment, and rats showed increased locomotion. After
2 mg/kg treatment, ERK phosphorylation increased and rat motility started to decrease. After treating
with 4–8 mg/kg, ERK phosphorylation once again decreased and rats showed hypomotility and ataxia.
ERK phosphorylation levels were maintained from 15 min to 90 min after 1 or 2 mg/kg treatment.
Ser338-c-Raf andMEK phosphorylation showed similar dose-dependent and temporal patterns to those of
ERK. Taken together, Ser338-c-Raf-MEK-ERK phosphorylation byMK-801 in the rat frontal cortex showed
a specific pattern and may be associated with behavioural changes induced by MK-801.
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Introduction
NMDA receptor hypofunction has been suggested as
an aetiology of schizophrenia (Deutsch et al., 2002;
Olney and Farber, 1995), and the non-competitive
NMDA receptor antagonist MK-801 is known to have
psychotomimetic effects that closely resemble the
symptoms of schizophrenia (Olney and Farber, 1995).
Moreover, behavioural changes induced by MK-801 in
rodents, including hyperlocomotion, stereotyped
sniffing, and ataxia, are considered pharmacological
measures of NMDA hypofunction in living animals
(Andine et al., 1999, Deutsch et al., 2002).
The intracellular signal transduction pathways
of psychotomimetics have been studied in investiga-
tions into the biochemical mechanisms underlying
psychotic symptoms. Svenningsson et al. (2003)
reported that various psychotomimetics, such as
d-amphetamine, lysergic acid diethylamide (LSD) and
phencyclidine (PCP), affect the phosphorylation of
DARPP-32, GSK-3b, and CREB in the mouse frontal
cortex, and our group previously observed that MK-
801 influences c-fos expression (Ahn et al., 2002) and
the phosphorylation of Akt, GSK-3b, and CREB in the
rat frontal cortex (Ahn et al., 2005).
The ERK pathway is known to be an essential
component of NMDA receptor-related signal trans-
duction (Bading and Greenberg, 1991; Krapivinsky
et al., 2003), and the activity of ERK, downstream of
Ras, has been reported to be increased by NMDA
activation (Bading and Greenberg, 1991). Moreover,
MK-801 reduces the NMDA receptor-mediated
hyperphosphorylation of ERK2 in cortical neuronal
cultures (Chandler et al., 2001). Schizophrenia has
been suggested to be associated with ERK signalling
abnormalities in the thalamus and cerebellum
(Kyosseva, 2004), and atypical antipsychotics were
reported to activate ERK in the mouse cortex and in
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primary cultures of rat cortical neurons (Lu et al.,
2004; Valjent et al., 2004). In addition, ERKs are known
to be involved in both synaptic plasticity and long-
term potentiation (Orban et al., 1999), which are re-
lated to the pathophysiology of schizophrenia and the
action mechanism of antipsychotics and MK-801
(Carboni et al., 2004).
c-Raf is one of the main effectors to activate the
MEK-ERK pathway, and is recruited by GTP-bound
Ras (Avruch et al., 1994). The phosphorylation of c-Raf
at Ser338 is known to be essential for c-Raf activation
(Diaz et al., 1997; Goetz et al., 2003), and the hyper-
phosphorylation of c-Raf at Ser259 is known to inter-
fere with c-Raf activation (Moelling et al., 2002).
In this study, we observed that the effect of MK-801
on the phosphorylation of the Ser338-c-Raf-MEK-ERK
pathway is not unidirectional, and that the phosphor-
ylation level of this pathway in the rat frontal cortex
may be related to specific behavioural patterns in-
duced by MK-801.
Materials and methods
Animals and drug treatment
Male Sprague–Dawley rats (150–200 g) were grouped
and maintained under a 12-h light/dark cycle with
food and water freely available. Animals were treated
in accordance with the NIH Guide for the Care and
Use of Laboratory Animals.
MK-801 (Tocris, Ellisville, MO, USA, dissolved in
normal saline) was injected into rats intraperitoneally
(i.p.) and control animals received an identical volume
of normal saline. To examine the relation betweenMK-
801 dosage and phosphorylation of c-Raf, MEK and
ERK phosphorylation, we observed phosphorylation
levels 60 min after MK-801 injection because our pre-
liminary results showed that ERK1/2 phosphorylation
decreased maximally at 60 min after MK-801 admin-
istration. Moreover, it has been reported that MK-801-
induced locomotion, stereotyped sniffing, and ataxia
are fully and stably developed at 60 min after treat-
ment (Andine et al., 1999). We observed the phos-
phorylation levels of c-Raf, MEK, and ERK at 15, 30,
60, and 90 min after injection of 1 or 2 mg/kg MK-801
in order to examine the temporal profile of phosphor-
ylation. Three independent experiments were per-
formed at each MK-801 dosage and time-point.
Behavioural experiments
After administration of MK-801, rats were placed in
individual standard clear plastic cages (26r42r
18 cm) bedded with wood chips. We observed and
rated the behaviours of rats 60 min after injection
of each MK-801 dose for 30 s. We rated locomotion,
stereotyped sniffing, and ataxia using the rating scales
described by Andine et al. (1999). Locomotion scores
were rated from 0 to 5, stereotyped sniffing from 0 to 2,
and ataxia from 0 to 3. Higher scores were awarded to
more pronounced behavioural patterns. Scores were
obtained from three independent experiments.
Western blot analysis
Brains were dissected on ice plates. Frontal cortices
were immediately homogenized in 10 vol (v/w) of
pre-chilled buffer containing 25 mM Hepes (pH 7.9),
200 mM NaCl, 1.5 mM MgCl2, 0.2% NP-40, 1 mM DTT,
0.5 mM EDTA, 1 mM PMSF, 20 mM b-glycerophos-
phate, 2 mM NaF, 0.1 mM Na3VO4, 2 mg/l leupeptin
and protease inhibitor cocktail (Roche, Mannheim,
Germany). Homogenates were centrifuged and su-
pernatants were boiled with Laemmli sample buffer.
Proteins were then fractionated in 8% SDS–PAGE
gel and transferred to nitrocellulose membranes
(Schleicher & Schuell Bioscience, Dassel, Germany).
Membranes were incubated with ERK1/2, p-ERK1/2
(Thr202/Tyr204), MEK1/2, pMEK1/2 (Ser217/204),
c-Raf, p-c-Raf (Ser259) or p-c-Raf-(Ser338) specific
antibodies (all from Cell Signaling Technology,
Beverly, MA, USA) at a dilution of 1:1000–3000 over-
night at 4 xC. Membranes were then incubated with
anti-rabbit IgG conjugated to horseradish peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
signals were detected using an ECL system (Pierce,
Rockford, IL, USA). Film exposure was adjusted as
indicated by preliminary experiments.
Statistical analysis
At least three independent experiments were per-
formed. The non-parametric Mann–Whitney U test
was used to analyse average values, and p values of
<0.05 were considered statistically significant.
Results
We examined the effect of MK-801 in the rat frontal
cortex on each dose (0.25, 0.5, 1, 2, 4, and 8 mg/kg)
60 min after i.p. injection of MK-801. The phosphor-
ylation of Thr202/Tyr204-ERK showed a different
pattern according to the dosage of MK-801. At MK-801
dosages from 0.25 to 1 mg/kg, ERK2 phosphorylation
levels markedly reduced compared to vehicle-treated
controls. At 2 mg/kg, ERK2 phosphorylation levels
increased vs. baseline, and between 4 and 8 mg/kg
ERK2 phosphorylation decreased again. We also
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observed an ERK1 signal (44 kDa, upper bands in
Figure 1a) above ERK2, and phospho-ERK1 above
phospho-ERK2. These phospho-ERK1 signals were
much weaker than ERK2 and could not be quantified,
but they showed a similar pattern to those of phospho-
ERK2 (Figure 1).
The phosphorylation of Ser217/Ser221-MEK, im-
mediately upstream of ERK, and of Ser338-c-Raf
showed a similar dose-dependent pattern to that of
ERK. At doses of 0.25–1 mg/kg MK-801, the phos-
phorylation levels of Ser217/Ser221-ME̊K and Ser338-
c-Raf decreased. Phosphorylation increased when
MK-801 was administered at 2 mg/kg and decreased
again when MK-801 was administered at 4–8 mg/kg.
However, MK-801 administration did not affect
Ser259-c-Raf phosphorylation or the total amounts of
ERK, MEK, or c-Raf (Figure 1).
Rat behaviour also changed with MK-801 dosage.
At baseline, after i.p. injection of an equivalent volume
of normal saline, locomotion, stereotyped sniffing,
and ataxia scores were 0.33¡0.58, 1.33¡0.58 and
0.00¡0.00 (mean¡S.D.) respectively. At MK-801 doses
of 0.25–1 mg/kg, rats showed increased locomotion
and stereotyped sniffing (locomotion, stereotypy, and
ataxia at 1 mg/kg: 1.67¡0.58, 2.00¡0.00 and 1.33¡
0.58 respectively). However, after treatment with
2 mg/kg MK801, locomotion decreased, although it
was still higher than that of vehicle-treated rats (loco-
motion, stereotypy, and ataxia; 0.33¡0.58, 1.67¡0.58
and 3.00¡0.00 respectively). Moreover, from 4 to
8 mg/kg MK801, rats showed hypomotility and ataxia
(locomotion, stereotypy and ataxia : 0.00¡0.00, 0.00¡
0.00 and 3.00¡0.00 respectively). These behavioural
changes seem to be related to MK801-induced phos-
phorylation level changes in Thr202/Tyr204-ERK2,
Ser217/Ser221-MEK and Ser338-c-Raf in the rat frontal
cortex. At lower MK-801 dosages (0.25–1 mg/kg), rat
motility increased whereas ERK, MEK, and Ser338-
c-Raf phosphorylation decreased, and when rats
showed a transition from hypermotility to hypo-
motility at 2 mg/kgMK-801, ERK, MEK, and Ser338-c-
Raf phosphorylation increased significantly vs. base-
line. Moreover, when the rats showed hypomotility
and ataxia these phosphorylation levels decreased
again.
After administration of 1 mg/kg MK-801, ERK2
phosphorylation was observed to be reduced from
15 min post-injection and this was maintained until
90 min. Ser338-c-Raf and MEK phosphorylation levels
were also attenuated from 15 to 90 min after MK-801
injection (Figure 2).
After injecting 2 mg/kg MK-801, ERK2 phosphor-
ylation was increased from 15 min to 90 min post-in-
jection; Ser338-c-Raf and MEK showed similar
patterns to those of ERK (Figure 3).
Discussion
We examined the effect of MK-801 on the c-Raf-MEK-
ERK pathway in the rat frontal cortex in vivo. The
phosphorylation levels of Ser338-c-Raf, MEK, and
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Figure 1. MK-801 dose-dependent patterns of c-Raf, MEK
and ERK phosphorylation in the rat frontal cortex. (a)
Immunoblots of rat frontal cortex 60 min after treatment
with MK-801 at the indicated doses. (b) Quantification of
immunoblot data by densitometry. Three independent
experiments were performed. Data are expressed as relative
optical densities (ODs) and represent the average values and
standard deviations of three independent experiments. The
relative ODs are quoted as percentages vs. the OD of the
sham-treated group. S and V indicate the sham- and vehicle-
treated controls respectively. The asterisks (*) indicate
significant difference of OD of each dose from the OD of
vehicle (p<0.05, Mann–Whitney U test).
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4–8 mg/kgMK-801, but increased after administration
of 2 mg/kg MK-801. Moreover, these phosphorylation
level changes were maintained from 15 to 90 min after
administration of 1 or 2 mg/kg MK-801. These results
suggest that the Ser338-c-Raf-MEK-ERK pathway
in the rat frontal cortex may be one of the signalling
pathways involved in the action mechanism of
MK-801.
ERK phosphorylation was reduced with 1 mg/kg
MK-801, but increased by 2 mg/kg MK-801. In
addition, we reported that c-fos induction and Akt-
GSK-3b phosphorylation were increased by 1 mg/kg
MK-801, and then started to decrease with 2 mg/kg
MK-801. The ERK phosphorylation level decreased
again with 4–8 mg/kg MK-801, and c-fos expression
and phosphorylation of Akt and GSK-3b were also
attenuated (Ahn et al., 2002, 2005). These results sug-
gest that intracellular signalling pathways respond
differently to different MK-801 dosages, and that ERK
phosphorylation differences after 0.25–1 mg/kg,
2 mg/kg, or 4–8 mg/kg administration of MK-801 re-
flect different states of neuronal activation in the rat
frontal cortex.
Interestingly, rat behaviour and ERK phosphoryla-
tion levels in the rat frontal cortex depended on MK-
801 dosage. At a dose of 1 mg/kg MK-801, rats
showed increased locomotion. However, at 2 mg/kg
MK-801, rat motility started to reduce, and at>2 mg/
kg rats showed hypomotility and ataxia. Andine et al.
(1999) reported that rats showed maximal behavioural
activation in terms of locomotion and stereotyped
sniffing at 1 mg/kg MK-801, whereas, at 3 mg/kg,
they showed extensive ataxia without locomotion. It
has been reported that a blood–brain barrier pen-
etrating MEK inhibitor (SL327) blocking the ERK
pathway increased locomotion time and distance
travelled in a large open field in a manner similar to
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Figure 3. Temporal patterns of c-Raf, MEK and ERK
phosphorylation in the rat frontal cortex after administration
of 2 mg/kg MK-801 i.p. (a) Immunoblots of the rat frontal
cortex at the indicated times after treatment with 2 mg/kg
MK-801. (b) Quantification of immunoblot data by
densitometry (performed as described in Figure 1 legend).
&, Sham (S) ; %, vehicle (V); , MK-801.
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Figure 2. Temporal patterns of c-Raf, MEK and ERK
phosphorylation in the rat frontal cortex after administration
of 1 mg/kg MK-801 i.p. (a) Immunoblots of rat frontal cortex
after treatment with MK-801 (1 mg/kg) for the indicated
periods. (b) Quantification of immunoblot data by
densitometric analysis of band intensities (performed as
described in Figure 1 legend). &, Sham (S) ; %, vehicle (V);
, MK-801.
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that induced by amphetamine (Einat et al., 2003),
which is known to induce schizophrenia-like psy-
chosis. Therefore, it may be presumed that specific
patterns of ERK signalling pathways in the rat frontal
cortex may have some association with the state of
brain activation, which could result in specific patterns
of behaviour – including the psychotomimetic effect of
MK-801.
The changes in ERK phosphorylation by MK-801
could be explained in several ways. First, ERK signal-
ling may be positively or negatively regulated by
PI3-kinase (PI3K). The activation of ERK by NMDA
receptor stimulation has been reported to completely
or partially depend on PI3K activity (Chandler et al.,
2001; Opazo et al., 2003), although, it has also been
suggested that PI3K activation inhibits ERK activation
(Zimmermann and Moelling, 1999). The relationship
between PI3K and ERK is known to be dependent on
cell type, type of stimulus, and strength of signal
(Duckworth and Cantley, 1997; Wennstrom and
Downward, 1999; Zhuang et al., 2004). Previously, our
group observed that MK-801 increases the phosphor-
ylation of Ser9-GSK-3b, Ser133-CREB, and Ser473-Akt
in the rat frontal cortex, thus implicating PI3K path-
way activation (Ahn et al., 2005). According to our re-
sults, administration of MK-801 from 0.25 to 1 mg/kg
caused ERK phosphorylation to decrease, but Akt-
GSK-3b phosphorylation to increase; however, at
2 mg/kg MK-801, ERK and Akt-GSK-3b phosphor-
ylation increased, and at 4–8 mg/kg both decreased.
According to these results, the interaction in the
phosphorylation between ERK and Akt-GSK-3b may
not show apparent cross-talk. Furthermore, it has been
reported that Akt can phosphorylate c-Raf on Ser259,
and that this results in ERK activity inhibition
(Moelling et al., 2002), but the phosphorylation on
Ser259 was unaffected by MK-801 treatment, as pre-
viously mentioned. Under our experimental condi-
tions, changes in ERK phosphorylation did not seem
to be attributable to an interaction between the PI3K
and ERK pathways.
Second, reduced Ser338-c-Raf-MEK-ERK phos-
phorylation may have been due to the inactivation of
NMDA receptor activity by MK-801. However, this
hypothesis is incompatible with the finding that MK-
801 at a dose of 2 mg/kg increased ERK phosphor-
ylation, but MK-801 at a higher dosage reduced ERK
phosphorylation. Chandler et al. (2001) reported that
the dose–response curve for the stimulation of phos-
pho-ERK2 by NMDA is biphasic in cortical neuronal
cultures, and that the possibility that MK-801 influ-
ences ERK activity via a mechanism independent of
the NMDA receptor cannot be excluded (Olney and
Farber, 1995). Taken together with our findings, these
observations suggest that a simple linear relation be-
tween NMDA receptor activity and ERK phosphor-
ylation is unlikely.
Finally, changes in ERK phosphorylation induced
by MK-801 could be explained by an alteration in the
deactivation of kinase, i.e. a changed phosphatase
activity. The contribution of phosphatase activation
cannot be ruled out as a possible reason for the change
in altered ERK phosphorylation by MK-801, because
we did not measure phosphatase activities. Further
studies on the regulation of phosphatase activity by
MK-801 may shed new light on this possibility.
In summary, the present study shows that the effect
of MK-801 on the phosphorylation of the Ser338-c-Raf-
MEK-ERK pathway in the rat frontal cortex is not
unidirectional, and that the phosphorylation of this
pathway in the rat frontal cortex may play an import-
ant role in specific patterns of behaviour, including the
psychotomimetic effect, induced by MK-801.
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